Investing.com - GeneDx Holdings (NASDAQ: WGS) reported second quarter EPS of $-1.84, $1.74 worse than the analyst estimate of $-0.10. Revenue for the quarter came in at $48.71M versus the consensus estimate of $52.76M.
GeneDx Holdings's stock price closed at $6.65. It is down -3.34% in the last 3 months and down -89.05% in the last 12 months.
GeneDx Holdings saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See GeneDx Holdings's stock price’s past reactions to earnings here.
According to InvestingPro, GeneDx Holdings's Financial Health score is "fair performance".
Check out GeneDx Holdings's recent earnings performance, and GeneDx Holdings's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar